A comparison of the effects of botulinum toxin A and steroid injection on nasal allergy

Abstract

Objectives

To compare the effects of botulinum toxin A (BTX-A) with intranasal steroid injections on nasal symptoms in patients with allergic rhinitis (AR).

Study Design

A randomized, placebo-controlled, single-blinded clinical trial (patients were blinded).

Material and Methods

Thirty-nine patients were included in the study. AR was diagnosed by means of history, clinical examination, and skin prick test. Patients were randomly divided into three subgroups as follows: in group A, 25 units of BTX-A were injected into each inferior turbinate (total 50 units); in group B, 1 cc (20 mg/mL) of triamcinolone was injected into each inferior turbinate; and in group C, 1 cc of isotonic saline was injected as placebo. The symptoms of AR were scored by the patient on a six-point scale.

Results

At all time points, group A was significantly better than group C. In the nasal obstruction and rhinorrhea scores, group A was significantly better than group B after 8 weeks.

Conclusion

BTX-A may provide better AR symptom relief in terms of duration and degree than a steroid injection.

Get full access to this article

View all access options for this article.

References

Aberg

Asthma and allergic rhinitis in Swedish conscripts. Clin Exp Allergy 1989;198:959–63.

Ayars

Non allergic rhinitis. Immunol Allergy Clin North Am 2000;20:283–302.

Schantz

Johnson

Properties and uses of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56:80–99.

Lance

Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol 2004;44:16–193.

James

Botulinum toxin-physiology and application in head and neck disorders. Head Neck 2005;27:525–35.

Shaari

Sanders

, et al. Rhinorrhea is decreased in dogs after nasal application of botulinum toxin. Otolaryngol Head Neck Surg 1995;112:566–71.

Kim

Yoon

, et al. The effect of botulinum toxin type A injections for intrinsic rhinitis. J Laryngol Otol 1998;121:248–51.

Rohrbach

Olthoff

Laskwawi

, et al. Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs. Ann Otol Rhinol Laryngol 2001;110:1045–50.

Murat

Serhan

Okan

, et al. Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial. Acta Otolaryngol 2003;123:1060–3.

10.

Schantz

Johnson

Properties and uses of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992;56: 80–99.

11.

Dogu

Apaydin

Sevim

, et al. Ultrasound guided versus blind intraparotid injections of botulinum toxin-A for the treatment of sialorrhea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106:93–6.

12.

Scott

Suzuki

Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1982;170:149–59.

13.

Rohrbach

Olthoff

Laskwawi

, et al. Minimally invasive application of botulinum toxin type A in nasal hypersecretion. ORL J Otorhinolaryngol Relat 2001;63:382–4.

14.

Ozcan

Vayisoglu

Okan

, et al. The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis. Am J Otolaryngol 2006;27:314–8.

15.

Martin

Church

Petti

, et al. Visual loss after intraturbinate steroid injection. Otolarnygol Head Neck Surg 2003;12:280–1.

16.

Jaradeh

Smith

Torrico

, et al. Autonomic nervous system evaluation of patients with vasomotor rhinitis. Laryngoscope 2000;110:1828–31.

17.

Wilde

Cook

Jones

The nasal response to axillary pressure in non-eosinophilic intrinsic rhinitis. Clin Otolaryngol 1997;22: 219–21.

18.

Unal

Sevim

Dogu

, et al. Effect of botulinum toxin type A on nasal symptoms in patients with allergic rhinitis: a double-blind, placebo-controlled clinical trial. Acta Otolaryngol 2003;123:1060–3.